Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Ash 2021 – Bristol reveals its sons of Revlimid
Data in multiple myeloma and non-Hodgkin’s lymphoma make Bristol optimistic about follow-ons to Revlimid and Pomalyst.
Bayer beefs up discovery work with Vividion buyout
Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.
